Neurology · Clinical trials
Tourette Syndrome Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About tourette syndrome — and why its trials are hard
Tourette syndrome is a childhood-onset neurodevelopmental disorder defined by multiple motor tics and at least one vocal/phonic tic persisting more than a year, frequently accompanied by ADHD and OCD. Tics often wax and wane and may improve in adulthood, so treatment targets impairment rather than tic elimination, beginning with behavioral therapy (Comprehensive Behavioral Intervention for Tics, CBIT). Pharmacologically, the best-evidenced agents are dopamine-blocking antipsychotics: haloperidol and pimozide (Orap) are FDA-approved, and aripiprazole (Abilify) gained FDA approval for pediatric Tourette's in 2014, though metabolic and movement side effects temper their use. Alpha-2 agonists (clonidine, guanfacine) are widely used off-label, especially with comorbid ADHD. VMAT2 inhibitors have disappointed: deutetrabenazine (Austedo) failed its pivotal pediatric ARTISTS trials. The selective dopamine-1 antagonist ecopipam has shown promising phase 2b/3 results and is in late development. A defining challenge across Tourette trials is the very high placebo response, which repeatedly complicates demonstrating drug efficacy on the primary Yale Global Tic Severity Scale (YGTSS).
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Haloperidol (Haldol) | 1969 (long-established Tourette labeling) | Suppression of motor/vocal tics in Tourette syndrome | Older randomized/controlled tic studies | Reduction in tic frequency/severity | Effective tic suppression but limited by sedation, extrapyramidal effects, and tardive risk |
| Pimozide (Orap) | 1984 | Suppression of tics in Tourette syndrome not responding adequately to other treatment | Randomized placebo/active-controlled trials | Reduction in tic severity | Significant tic reduction; QT prolongation and drug-interaction cautions limit dosing |
| Aripiprazole (Abilify) | 2014 | Pediatric patients (6-18) with Tourette's disorder | Randomized double-blind placebo-controlled pediatric trial | Change in Yale Global Tic Severity Scale Total Tic Score (YGTSS-TTS) | Significant YGTSS-TTS reduction versus placebo; generally better tolerated than typical antipsychotics |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in tourette syndrome development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Deutetrabenazine (VMAT2 inhibitor) — ARTISTS 1 and ARTISTS 2 (Phase 2/3, Teva) in pediatric Tourette | Failed to meet primary YGTSS-TTS endpoint versus placebo; program did not advance to approval | Very high placebo response and insufficient drug-placebo separation in pediatric tic trials |
| Tetrabenazine (off-label) — Small open-label tic studies | Limited controlled evidence; not FDA-approved for tics | Sedation, depression, and parkinsonism limit use; lacks robust randomized support in Tourette |
Choosing the right endpoint
Primary endpoints that matter in tourette syndrome trials
- YGTSS (Yale Global Tic Severity Scale) — Primary endpoint (often the Total Tic Score) across modern Tourette trials
- CGI-I (Clinical Global Impression - Improvement) — Global responder measure of overall tic-related improvement
- Premonitory Urge for Tics Scale (PUTS) — Captures the sensory urge preceding tics, relevant to behavioral therapy
- Comorbidity scales (ADHD/OCD) — Important secondary measures given frequent coexisting conditions
- Placebo-response assessment — Critical design consideration due to consistently high placebo effects in tic trials
How iNGENū runs tourette syndrome trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Tourette Syndrome clinical trials — FAQs
What medications are FDA-approved for Tourette syndrome?
Why do Tourette drug trials often fail?
Is ecopipam approved for Tourette syndrome?
Ready to discuss your tourette syndrome trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal